Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

NewsGuard 100/100 Score

Agilent Technologies Inc. (NYSE:A) today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

“The new columns greatly expand our current bio-columns portfolio, which also include reverse phase columns for intact protein separations and peptide mapping.”

“With the addition of these new bio-columns, we can now offer our customers significant improvements in charge-based and size-based analytical separations of bio-molecules,” said Helen Stimson, vice president and general manager of Agilent’s Consumables and Supplies Division. “The new columns greatly expand our current bio-columns portfolio, which also include reverse phase columns for intact protein separations and peptide mapping.”

Each new column is individually tested with protein samples to ensure column-to-column and batch-to-batch reproducibility. The four new column families and their benefits include:

  • Agilent Bio SEC-3 size exclusion columns, packed with a robust 3µm particle, which offers higher resolution and faster separation times, specifically for the analysis of monoclonal antibody aggregates;
  • Agilent Bio SEC-5 size exclusion columns, packed with 5μm particles coated with a neutral, hydrophilic coating, making the particle extremely stable under harsh buffer conditions;
  • Agilent Bio MAb columns, featuring a weak cation exchange (WCX) resin specifically designed for high-resolution separations of monoclonal antibody charge variants; and
  • Agilent Bio IEX columns, designed for high-resolution, high-recovery and highly efficient separations of proteins, peptides, oligonucleotides and other bio-molecules.

Size exclusion chromatography is commonly used for the analysis of protein aggregation when proteins bind together to form a larger complex. Ion exchange chromatography is regularly used to monitor the reproducibility of protein manufacturing. Charge variants are carefully monitored, specifically glycosylation and deamidation, to ensure safety and efficacy. Additional information about the new Agilent BioHPLC columns is available at www.agilent.com/chem/biohplc.

Source Agilent Technologies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blood protein could be a potential biomarker for delayed concussion recovery in children